Cantrixil, formerly known as TRX-E-002-1, is a potent and selective SMETI inhibitor. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo. TRX-E-002-1 may fill the current need for better therapeutic options in the control and management of recurrent ovarian cancer and may help improve patient survival References: Saif MW, Heaton A, Lilischkis K, Garner J, Brown DM. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1). Cancer Chemother Pharmacol. 2017 Feb;79(2):303-314. doi: 10.1007/s00280-016-3224-2. Epub 2016 Dec 24. Review. PubMed PMID: 28013349; PubMed Central PMCID: PMC5306062.

纯度：≥98%

CAS：2135511-22-5